Published in Gene Therapy Weekly, August 18th, 2005
Under the terms of the agreement, Xencor's XmAb engineered antibody Fc domains will be used to create antibody drug candidates that Centocor will evaluate against an oncology target. Xencor will receive an upfront payment and is eligible to receive additional license fees, milestones and royalties in the event that Centocor advances candidates into development. Specific financial terms were not disclosed.
Xencor's XmAb engineered Fc domains are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.